Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness.

Jackson E, Zhang CX, Kiani Z, Lisovsky I, Tallon B, Del Corpo A, Gilbert L, Bruneau J, Thomas R, Côté P, Trottier B, LeBlanc R, Rouleau D, Tremblay C, Tsoukas CM, Routy JP, Ni X, Mabanga T, Bernard NF; Montreal Primary Infection Study Group.

PLoS One. 2017 Sep 22;12(9):e0185160. doi: 10.1371/journal.pone.0185160. eCollection 2017.

2.

Comprehensive evaluation of the immune risk phenotype in successfully treated HIV-infected individuals.

Ndumbi P, Gilbert L, Tsoukas CM.

PLoS One. 2015 Feb 3;10(2):e0117039. doi: 10.1371/journal.pone.0117039. eCollection 2015.

3.

Time to seroconversion in HIV-exposed subjects carrying protective versus non protective KIR3DS1/L1 and HLA-B genotypes.

Tallon BJ, Bruneau J, Tsoukas CM, Routy JP, Kiani Z, Tan X, Bernard NF.

PLoS One. 2014 Oct 17;9(10):e110480. doi: 10.1371/journal.pone.0110480. eCollection 2014.

4.

Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.

Samji H, Taha TE, Moore D, Burchell AN, Cescon A, Cooper C, Raboud JM, Klein MB, Loutfy MR, Machouf N, Tsoukas CM, Montaner JS, Hogg RS; Canadian Observational Cohort (CANOC) Collaboration.

HIV Med. 2015 Feb;16(2):76-87. doi: 10.1111/hiv.12173. Epub 2014 Sep 1.

5.

Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort.

Ndumbi P, Gillis J, Raboud JM, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas CM; Canadian Observational Cohort (CANOC) collaboration.

AIDS. 2013 Nov 28;27(18):2863-72. doi: 10.1097/01.aids.0000432471.84497.bc.

PMID:
25119689
6.

Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.

Ndumbi P, Falutz J, Pant Pai N, Tsoukas CM.

PLoS One. 2014 Apr 7;9(4):e94018. doi: 10.1371/journal.pone.0094018. eCollection 2014.

7.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.

PMID:
23664333
8.

Adult primary immune deficiency: what are we missing?

Srinivasa BT, Alizadehfar R, Desrosiers M, Shuster J, Pai NP, Tsoukas CM.

Am J Med. 2012 Aug;125(8):779-86. doi: 10.1016/j.amjmed.2012.02.015. Epub 2012 Jun 9.

PMID:
22682795
9.

Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors.

Kamya P, Tallon B, Melendez-Pena C, Parsons MS, Migueles SA, Connors M, Miconiatis S, Song R, Boulet S, Bruneau J, Tremblay CL, Bernard NF; investigators of the Canadian Cohort of HIV Infected Slow Progressors.

Clin Immunol. 2012 Jun;143(3):246-55. doi: 10.1016/j.clim.2012.01.001. Epub 2012 Jan 15.

PMID:
22445844
10.

T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers.

Kamya P, Tsoukas CM, Boulet S, Routy JP, Thomas R, Côté P, Boulassel MR, Lessard B, Kaul R, Ostrowski M, Kovacs C, Tremblay CL, Bernard NF.

AIDS Res Ther. 2011 Jun 16;8(1):20. doi: 10.1186/1742-6405-8-20.

11.

Relative contribution of HIV-specific functional lymphocyte subsets restricted by protective and non-protective HLA alleles.

Peretz Y, Marra O, Thomas R, Legault D, Côté P, Boulassel MR, Rouleau D, Routy JP, Sékaly RP, Tsoukas CM, Tremblay C, Bernard NF.

Viral Immunol. 2011 Jun;24(3):189-98. doi: 10.1089/vim.2010.0117.

PMID:
21668360
12.

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors.

J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6.

13.

Mind the gap: lack of association between KIR3DL1*004/HLA‐Bw4-induced natural killer cell function and protection from HIV infection.

Parsons MS, Boulet S, Song R, Bruneau J, Shoukry NH, Routy JP, Tsoukas CM, Bernard NF.

J Infect Dis. 2010 Nov 1;202 Suppl 3:S356-60. doi: 10.1086/655966.

PMID:
20887224
14.

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K; GRACE (Gender, Race, And Clinical Experience) Study Group.

Ann Intern Med. 2010 Sep 21;153(6):349-57. doi: 10.7326/0003-4819-153-6-201009210-00002.

15.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa.

Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.

PMID:
20085491
16.

HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells.

Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF.

J Immunol. 2010 Feb 15;184(4):2057-64. doi: 10.4049/jimmunol.0902621. Epub 2010 Jan 8.

17.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.

AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.

PMID:
19710593
18.

Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.

Huang KH, Loutfy MR, Boulet S, Toma E, Tsoukas CM, Bernard NF.

Antivir Ther. 2009;14(3):381-92.

PMID:
19474472
19.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

20.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

Supplemental Content

Loading ...
Support Center